OUR STORY

MISSION

Advancing healing and recovery beyond expectations.

  • 1985
    Founded as a spin-off of regenerative technology developed at the Massachusetts Institute of Technology (MIT).
  • 1998
    Apligraf® FDA-approved for the treatment of venous leg ulcers.
  • 2000
    Apligraf® FDA-approved for the treatment of diabetic foot ulcers.
  • 2004
    Launch of full U.S. sales and marketing organization.
  • 2006
    European office established in Switzerland.
  • 2014
    Acquired Dermagraft® for treatment of chronic diabetic foot ulcers.
  • 2015
    Launched new PuraPly® product line.
  • 2017
    Acquired NuTech Medical and expanded product portfolio to include surgical and sports medicine.
  • 2019
    ORGO began trading on the NASDAQ Stock Market.
  • 2021
    Launched Novachor™ placental allograft membrane covering for wounds.
  • 2022
    Launched PuraPly® MZ micronized wound matrix.

WHO WE ARE

Our 900+ dedicated team members are led by a passionate group of industry experts and medical professionals solely focused on elevating the standard of care by delivering life-changing solutions to those who need them most.

MEET OUR LEADERSHIP

WHAT WE DO

Organogenesis is a leading regenerative medicine company focused on empowering healing through the development, manufacturing, and sale of products for the advanced wound care and surgical and sports medicine markets.

EXPLORE ADVANCED
WOUND CARE
EXPLORE SPORTS &
SURGICAL MEDICINE

WHERE TRANSFORMATION LIVES

With corporate headquarters in Canton, MA, additional facilities in Birmingham, AL, St. Petersburg, FL, and our new Innovation Center in San Diego, CA, we're proud to be able to manufacture all our products right here in the United States. You can learn more about our quality standards by connecting with a team at any location.

CONTACT US

SAN DIEGO
CALIFORNIA

R&D + Commercial

BIRMINGHAM
ALABAMA

R&D

CANTON
MASSACHUSETTS

R&D + Commercial + Manufacturing

NORWOOD
MASSACHUSETTS

R&D

ST. PETERSBURG
FLORIDA

Commercial